Cargando…

Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials

SIMPLE SUMMARY: The mortality of hepatocellular carcinoma (HCC) is quickly increasing worldwide. Immunotherapy enables the immune defense of the organism to target liver cancer cells. Recent technologies enable engineering of immune cells, and notably T lymphocytes, to make them more efficient again...

Descripción completa

Detalles Bibliográficos
Autores principales: Rochigneux, Philippe, Chanez, Brice, De Rauglaudre, Bernadette, Mitry, Emmanuel, Chabannon, Christian, Gilabert, Marine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7828372/
https://www.ncbi.nlm.nih.gov/pubmed/33450845
http://dx.doi.org/10.3390/cancers13020271
_version_ 1783640996509122560
author Rochigneux, Philippe
Chanez, Brice
De Rauglaudre, Bernadette
Mitry, Emmanuel
Chabannon, Christian
Gilabert, Marine
author_facet Rochigneux, Philippe
Chanez, Brice
De Rauglaudre, Bernadette
Mitry, Emmanuel
Chabannon, Christian
Gilabert, Marine
author_sort Rochigneux, Philippe
collection PubMed
description SIMPLE SUMMARY: The mortality of hepatocellular carcinoma (HCC) is quickly increasing worldwide. Immunotherapy enables the immune defense of the organism to target liver cancer cells. Recent technologies enable engineering of immune cells, and notably T lymphocytes, to make them more efficient against the tumor. These technics (called TCR engineered T cells and CAR-T cells) are promising and are actually tested in clinical trials. This review explains the concept of TCR modified and CAR-T cells in liver cancer (targets and mechanisms of action) and reports the results from recent clinical trials. ABSTRACT: The mortality of hepatocellular carcinoma (HCC) is quickly increasing worldwide. In unresectable HCC, the cornerstone of systemic treatments is switching from tyrosine kinase inhibitors to immune checkpoints inhibitors (ICI). Next to ICI, adoptive cell transfer represents another promising field of immunotherapy. Targeting tumor associated antigens such as alpha-fetoprotein (AFP), glypican-3 (GPC3), or New York esophageal squamous cell carcinoma-1 (NY-ESO-1), T cell receptor (TCR) engineered T cells and chimeric antigen receptors (CAR) engineered T cells are emerging as potentially effective therapies, with objective responses reported in early phase trials. In this review, we address the biological rationale of TCR/CAR engineered T cells in advanced HCC, their mechanisms of action, and results from recent clinical trials.
format Online
Article
Text
id pubmed-7828372
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78283722021-01-25 Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials Rochigneux, Philippe Chanez, Brice De Rauglaudre, Bernadette Mitry, Emmanuel Chabannon, Christian Gilabert, Marine Cancers (Basel) Review SIMPLE SUMMARY: The mortality of hepatocellular carcinoma (HCC) is quickly increasing worldwide. Immunotherapy enables the immune defense of the organism to target liver cancer cells. Recent technologies enable engineering of immune cells, and notably T lymphocytes, to make them more efficient against the tumor. These technics (called TCR engineered T cells and CAR-T cells) are promising and are actually tested in clinical trials. This review explains the concept of TCR modified and CAR-T cells in liver cancer (targets and mechanisms of action) and reports the results from recent clinical trials. ABSTRACT: The mortality of hepatocellular carcinoma (HCC) is quickly increasing worldwide. In unresectable HCC, the cornerstone of systemic treatments is switching from tyrosine kinase inhibitors to immune checkpoints inhibitors (ICI). Next to ICI, adoptive cell transfer represents another promising field of immunotherapy. Targeting tumor associated antigens such as alpha-fetoprotein (AFP), glypican-3 (GPC3), or New York esophageal squamous cell carcinoma-1 (NY-ESO-1), T cell receptor (TCR) engineered T cells and chimeric antigen receptors (CAR) engineered T cells are emerging as potentially effective therapies, with objective responses reported in early phase trials. In this review, we address the biological rationale of TCR/CAR engineered T cells in advanced HCC, their mechanisms of action, and results from recent clinical trials. MDPI 2021-01-13 /pmc/articles/PMC7828372/ /pubmed/33450845 http://dx.doi.org/10.3390/cancers13020271 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Rochigneux, Philippe
Chanez, Brice
De Rauglaudre, Bernadette
Mitry, Emmanuel
Chabannon, Christian
Gilabert, Marine
Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials
title Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials
title_full Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials
title_fullStr Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials
title_full_unstemmed Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials
title_short Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials
title_sort adoptive cell therapy in hepatocellular carcinoma: biological rationale and first results in early phase clinical trials
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7828372/
https://www.ncbi.nlm.nih.gov/pubmed/33450845
http://dx.doi.org/10.3390/cancers13020271
work_keys_str_mv AT rochigneuxphilippe adoptivecelltherapyinhepatocellularcarcinomabiologicalrationaleandfirstresultsinearlyphaseclinicaltrials
AT chanezbrice adoptivecelltherapyinhepatocellularcarcinomabiologicalrationaleandfirstresultsinearlyphaseclinicaltrials
AT derauglaudrebernadette adoptivecelltherapyinhepatocellularcarcinomabiologicalrationaleandfirstresultsinearlyphaseclinicaltrials
AT mitryemmanuel adoptivecelltherapyinhepatocellularcarcinomabiologicalrationaleandfirstresultsinearlyphaseclinicaltrials
AT chabannonchristian adoptivecelltherapyinhepatocellularcarcinomabiologicalrationaleandfirstresultsinearlyphaseclinicaltrials
AT gilabertmarine adoptivecelltherapyinhepatocellularcarcinomabiologicalrationaleandfirstresultsinearlyphaseclinicaltrials